Tag: class action

NEW YORK CITY and NEW ORLEANS, July 22, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 25, 2025 to file lead plaintiff applications in securities class action lawsuits against Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS), if they purchased the Company’s securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”). These actions are pending in the United States District Court for the Northern District of California.

SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Easterly ROCMuni High Income Municipal Bond Fund f/k/a Principal Street High Income Municipal Fund (the “Easterly ROCMuni Fund”) (NYSE: RMJAX; RMHVK; RMHIX) shares between May 5, 2023 and June 12, 2025, inclusive (the “Class Period”), have until September 22, 2025 to seek appointment as lead plaintiff of the Easterly ROCMuni class action lawsuit. Captioned Victorson v. James Alpha Funds Trust d/b/a Easterly Funds Trust, No. 25-cv-06028 (S.D.N.Y.), the Easterly ROCMuni class action lawsuit charges the Easterly ROCMuni Fund, James Alpha Funds Trust d/b/a Easterly Funds Trust, investment adviser Easterly Investment Partners LLC and its former investment adviser Principal Street Partners, LLC, certain of the Easterly ROCMuni Fund’s underwriters, certain of their top executive officers and trustees, and others with violations of the Securities Exchange Act of 1933.

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Alto Neuroscience, Inc. (“Alto” or “the Company”) (NYSE: ANRO) and certain of its officers.

ATLANTA, July 22, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) complied with federal securities laws. On July 22, 2025, Replimune announced it received a Complete Response Letter (“CRL”) from the FDA regarding the Biologics License Application (“BLA”) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. In the CRL, the FDA indicated “that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.” Following this news, the price of the Company’s stock dropped. 

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma (URGN) To Contact Him Directly To Discuss Their Options

SAN FRANCISCO, July 21, 2025 (GLOBE NEWSWIRE) -- Healthcare giant Centene Corporation (NYSE: CNC), a prominent provider of government-sponsored and commercial healthcare services, finds itself embroiled in a class action lawsuit following a dramatic plunge in its stock price. The suit, Lunstrum v. Centene Corporation, No. 25-cv-05659 (S.D.N.Y.), seeks to represent investors who purchased or acquired Centene securities between December 12, 2024, and June 30, 2025, alleging violations of the Securities Exchange Act of 1934.

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG).

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Western District of Michigan on behalf of all persons or entities who purchased or otherwise acquired Neogen Corporation (“Neogen” or the “Company”) (NASDAQ: NEOG) securities between January 5, 2023 and June 3, 2025, both dates inclusive (the “Class Period”).

ATLANTA, July 21, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Fortrea Holdings, Inc. (“Fortrea” or the “Company”) (NASDAQ: FTRE). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about Fortrea’s business, operations, and prospects, including allegations that: (i) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company’s 2025 earnings; (ii) Fortrea overstated the cost savings it would likely achieve by exiting the transition services agreements; (iii) as a result, Fortrea’s previously announced EBITDA targets for 2025 were inflated; and (iv) accordingly, the viability of the Company’s post-Spin-Off business model, as well as its business and/or financial prospects, were overstated.

ATLANTA, July 21, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed Rocket Pharmaceuticals, Inc. (“Rocket Pharmaceuticals” or the “Company”) (NASDAQ: RCKT). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to adequately disclose that Rocket Pharmaceuticals knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk.

NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Vestis Corporation (NYSE: VSTS) between May 2, 2024 and May 6, 2025, both dates inclusive (the “Class Period”), of the important August 8, 2025 lead plaintiff deadline.

NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Broadmark Realty Capital Inc. (“Broadmark” or “the Company”) (NYSE: BRMK), Ready Capital Corporation ("Ready Capital") (NYSE: RC), and certain officers.